bioMerieux (OTCMKTS:BMXMF) Shares Gap Down – What’s Next?

bioMerieux (OTCMKTS:BMXMF)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $86.88, but opened at $83.27. bioMerieux shares last traded at $83.27, with a volume of 302 shares trading hands.

Analysts Set New Price Targets

BMXMF has been the topic of a number of recent analyst reports. Morgan Stanley reaffirmed an “underweight” rating on shares of bioMerieux in a research report on Friday. UBS Group downgraded shares of bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of bioMerieux in a research report on Wednesday, June 17th. Piper Sandler began coverage on bioMerieux in a research report on Thursday, June 11th. They issued a “neutral” rating on the stock. Finally, Zacks Research cut bioMerieux from a “hold” rating to a “strong sell” rating in a research note on Friday, July 31st. Four equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce”.

bioMerieux Stock Down 4.2%

The business’s 50 day moving average is $82.56 and its 200-day moving average is $90.38. The company has a quick ratio of 1.48, a current ratio of 2.39 and a debt-to-equity ratio of 0.08.

bioMerieux Company Profile

bioMérieux (OTCMKTS:BMXMF) is a France-based company specializing in in vitro diagnostics. It develops, manufactures and markets diagnostic systems used to detect infectious diseases, support antimicrobial treatment decisions and improve patient care in clinical settings.

The company’s product portfolio includes molecular biology tests, microbiology systems, immunoassays and syndromic testing solutions. Its clinical diagnostic products are used by hospitals, laboratories and other healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetic industries through solutions for detecting microorganisms and monitoring contamination.

Established in 1963, bioMérieux traces its roots to the Mérieux family’s longstanding involvement in medical research and diagnostics in France.